GSK-LSD1 dihydrochloride (b)

Research use only, not for human use.

GSK-LSD1 2HCl is a specificity irreversible LSD1 inhibitor (IC50: 16 nM). The selectivity of GSK-LSD1 for LSD1 is >1000 fold over other closely related FAD utilizing enzymes (i.e. MAO-A, LSD2, MAO-B).

GSK-LSD1 2HCl is a specificity irreversible LSD1 inhibitor (IC50: 16 nM). The selectivity of GSK-LSD1 for LSD1 is >1000 fold over other closely related FAD utilizing enzymes (i.e. MAO-A, LSD2, MAO-B).(In Vitro):GSK-LSD1 induces gene expression changes in cancer cell lines with average EC50 of < 5 nM and inhibits cancer cell line growth with average EC50 of < 5 nM.

GSK-LSD1 shows more than 1000 fold selectivity over other closely related FAD utilizing enzymes including LSD2, and monoamine oxidases MAO-A, MAO-B. GSK-LSD1 can inhibit KDM1A/LSD1 enzyme activity. GSK-LSD1 induces the formation of LC3-II in U2OS cells. The electronic microscopy shows the formation of autophagosome with GSK-LSD1 treatment. GSK-LSD1 potently inhibits proliferation of varies cancer cell lines by changing gene expression patterns.

——

GSK-LSD1 2HCl

Chromatin/Epigenetic

Histone Demethylase

glucosylceramide synthase

——

——

2102933-95-7

289.24

C14H22Cl2N2

>98% (HPLC)

In Vitro:?DMSO : ≥ 62.5 mg/mL (216.08 m)

Cl.Cl.C1[C@@H](NC2CCNCC2)[C@@H]1c1ccccc1

——

(-20℃)

With Ice Pack

≥ 2 years